Log In
BCIQ
Print this Print this
 

propagermanium and irbesartan (DMX-200)

  Manage Alerts
Collapse Summary General Information
Company Dimerix Ltd.
DescriptionTherapy comprising irbesartan, an angiotensin II type 1 (AT1) receptor (AGTR1) antagonist, and propagermanium, a CC chemokine receptor 2 (CCR2; CD192) antagonist
Molecular Target Angiotensin II type 1 (AT1) receptor (AGTR1) ; CC chemokine receptor 2 (CCR2) (CD192)
Mechanism of ActionCC chemokine receptor 2 (CCR2) antagonist; Angiotensin II type 1 (AT1) receptor (ATGR1) antagonist
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today